Summary of Ultragenyx Pharmaceutical FY Conference Call Company Overview - **Company**: Ultragenyx Pharmaceutical (NasdaqGS:RARE) - **Event**: 46th Annual TD Cowen Healthcare Conference - **Date**: March 02, 2026 Key Points on Angelman Syndrome - **Aspire Study**: Focused on Angelman syndrome with 130 patients aged 4 to 17 years, primarily with full deletions, aiming for a primary endpoint of cognition based on the Bayley-4 scale [3][4] - **Clinical Significance**: The meaningful score difference (MSD) for cognition is set at +5, with a mean difference of 10.9 observed in actively treated patients compared to a maximum change of 1 in the control group [4][5][6] - **Statistical Power**: The Aspire study is powered for greater than 90% success based on the statistical modeling of natural history data [6] - **Patient Population**: The study enrolls only patients with full deletions to ensure a homogeneous and severe patient population, minimizing variability and placebo effects [10][11] - **Aurora Study**: A phase II/III study supporting the broader Angelman product, focusing on safety and efficacy across different genotypes [14][15] - **Regulatory Strategy**: The Aspire study will form the basis of the approval package, with the Aurora study providing additional safety and efficacy data [16] Insights on Multi-Domain Responder Index (MDRI) - **Endpoints**: The MDRI is a key secondary endpoint, with both cognition and MDRI being treated as primary endpoints in the study [20][22] - **MSD for MDRI**: The MSD for the MDRI is also set at five points, with individual domains having specific MSDs [28][29] Discussion on Setrusumab and Bone Mineral Density - **Setrusumab**: The drug shows benefits in vertebral fractures and bone mineral density, with a focus on translating these findings into functional outcomes [36][37] - **FDA Interaction**: The company is strategizing on how to approach the FDA for accelerated approval based on compelling vertebral data and the need for confirmatory studies [38][39] Sanfilippo Syndrome and Manufacturing Challenges - **FDA Feedback**: The FDA indicated that clinical data is sufficient for approval, but there are challenges related to manufacturing and additional paperwork [46][48] - **Validation Period**: A 2-week validation period is expected for resubmission, with no new clinical data required [49][52] Gene Therapy and Market Considerations - **Unmet Medical Need**: Sanfilippo syndrome represents a high unmet medical need, with a small patient population but significant potential for successful product launch [71][72] - **Pricing Strategy**: The company believes that accelerated approval will not significantly impact pricing, as the focus remains on the high unmet need [43] Future Outlook - **Clinical Data**: Anticipation of data readouts for various studies, including the potential for accelerated approval and the importance of patient-level understanding in ongoing trials [42][75] - **Launch Preparedness**: The company is prepared to launch therapies for Sanfilippo and GSDIa quickly, having prioritized these programs for resource allocation [74] Conclusion - Ultragenyx Pharmaceutical is actively advancing its pipeline for rare diseases, particularly focusing on Angelman syndrome and Sanfilippo syndrome, while navigating regulatory challenges and ensuring robust clinical data to support its therapies.